WO2015155753A3 - Novel linkers and their uses in specific conjugation of drugs to biological molecule - Google Patents
Novel linkers and their uses in specific conjugation of drugs to biological molecule Download PDFInfo
- Publication number
- WO2015155753A3 WO2015155753A3 PCT/IB2015/056083 IB2015056083W WO2015155753A3 WO 2015155753 A3 WO2015155753 A3 WO 2015155753A3 IB 2015056083 W IB2015056083 W IB 2015056083W WO 2015155753 A3 WO2015155753 A3 WO 2015155753A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- linkers
- drugs
- biological molecule
- specific conjugation
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Abstract
Disclosed are linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic group for conjugation of two or more compounds/cytotoxic agents per linker to a cell-binding molecule through bridge linking pairs of thiols on the cell-binding molecule, as well as methods of making such linkers, of using such linkers in making homogeneous conjugates, and of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2015/056083 WO2015155753A2 (en) | 2015-08-10 | 2015-08-10 | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
CN201580082582.5A CN108289964B (en) | 2015-08-10 | 2015-08-10 | Novel linkers and their use for specific coupling of drugs and biomolecules |
CN202210788010.0A CN115300640A (en) | 2015-08-10 | 2015-08-10 | Novel linkers and their use for specific coupling of drugs and biomolecules |
JP2018506984A JP6817288B2 (en) | 2015-08-10 | 2015-08-10 | Its use in novel conjugates and specific conjugation of biomolecules with drugs |
CA2991975A CA2991975C (en) | 2015-08-10 | 2015-08-10 | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2015/056083 WO2015155753A2 (en) | 2015-08-10 | 2015-08-10 | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015155753A2 WO2015155753A2 (en) | 2015-10-15 |
WO2015155753A3 true WO2015155753A3 (en) | 2016-06-30 |
Family
ID=54288492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/056083 WO2015155753A2 (en) | 2015-08-10 | 2015-08-10 | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP6817288B2 (en) |
CN (2) | CN115300640A (en) |
CA (1) | CA2991975C (en) |
WO (1) | WO2015155753A2 (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7330515B2 (en) * | 2015-08-10 | 2023-08-22 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | Novel conjugates and their use in specific conjugation of biomolecules and drugs |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
AU2016202632B2 (en) | 2016-02-04 | 2021-09-09 | Hangzhou Dac Biotech Co, Ltd | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
CN106397226A (en) * | 2016-04-19 | 2017-02-15 | 福安药业集团宁波天衡制药有限公司 | Novel preparation method for tamoxifen |
BR112018071465A2 (en) * | 2016-04-20 | 2019-02-05 | Hangzhou Dac Biotech Co Ltd | amanita toxin derivatives and their conjugation to a cell binding molecule |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
KR20220147720A (en) * | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
NZ755835A (en) | 2017-01-17 | 2023-12-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
EP3601346A1 (en) * | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
CN116999573A (en) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | Antibody-drug conjugate, preparation method thereof, pharmaceutical composition and application thereof in preparation of drugs for treating tumors |
RU2020117698A (en) | 2017-12-01 | 2022-01-04 | Эббви Инк. | GLUCOCORTICOID RECEPTOR AGONIST AND ITS IMMUNOCONJUGATES |
WO2019109415A1 (en) * | 2017-12-04 | 2019-06-13 | 清华大学 | Compound for targeted degradation of hmgcr and application thereof |
CN109956972A (en) * | 2017-12-22 | 2019-07-02 | 四川科瑞德凯华制药有限公司 | Phosphinothioylidynetrisaziridine crystal form I and its preparation method and application |
MX2020006192A (en) * | 2017-12-31 | 2020-08-20 | Hangzhou Dac Biotech Co Ltd | A conjugate of a tubulysin analog with branched linkers. |
CN108586556B (en) * | 2018-01-17 | 2021-04-20 | 浙江海正药业股份有限公司 | Crystal form of pentostatin, preparation method and application thereof |
US20210309679A1 (en) * | 2018-07-23 | 2021-10-07 | Guangzhou Othrotx Co., Ltd. | Bisphosphonate drug conjugates |
WO2020033200A1 (en) * | 2018-08-09 | 2020-02-13 | Siemens Healthcare Diagnostics Inc. | Composition of a bilirubin stock and a method of preparation thereof |
AU2018445278B2 (en) * | 2018-10-12 | 2022-07-28 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers containing 2,3-diaminosuccinyl group |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
AU2019379418A1 (en) * | 2018-11-14 | 2021-06-03 | Daiichi Sankyo Company, Limited | Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate |
BR112021010982A2 (en) * | 2018-12-07 | 2021-08-31 | Oxford University Innovation Limited | BINDERS |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
EP3952916A1 (en) * | 2019-04-11 | 2022-02-16 | Sony Group Corporation | Programmable polymeric drugs |
US20220168435A1 (en) * | 2019-04-11 | 2022-06-02 | Sony Group Corporation | Programmable polymeric drugs |
SG11202111402PA (en) | 2019-05-14 | 2021-11-29 | Nuvation Bio Inc | Anti-cancer nuclear hormone receptor-targeting compounds |
CN110256313B (en) * | 2019-05-15 | 2021-01-29 | 江苏省原子医学研究所 | Photosensitizer prodrug compound and preparation method and application thereof |
US20230115871A1 (en) * | 2019-06-24 | 2023-04-13 | Hangzhou Dac Biotech Co., Ltd | A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers |
KR20220029725A (en) | 2019-06-29 | 2022-03-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Cell-binding molecule-tubulin derivative conjugate and method for preparing same |
CN112341521A (en) * | 2019-08-09 | 2021-02-09 | 上海翰森生物医药科技有限公司 | Small molecule active compound and antibody conjugate thereof, preparation method and medical application thereof |
CN110508029B (en) * | 2019-09-04 | 2022-01-28 | 武玉香 | Immunoaffinity column for simultaneously extracting florfenicol, chloramphenicol and thiamphenicol |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CN115569133B (en) * | 2020-02-26 | 2024-04-26 | 上海科技大学 | Use of methylindigoindigo against coronaviruses |
CN111393346B (en) * | 2020-06-02 | 2020-08-25 | 凯莱英生命科学技术(天津)有限公司 | Synthesis method of N-Boc-Dolaprine and Boc-Dap DCHA |
WO2022051591A2 (en) | 2020-09-04 | 2022-03-10 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
CN112285361B (en) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | Agent for eliminating interference of anti-CD 38 monoclonal antibody medicine against human globulin detection |
CN114478420A (en) * | 2020-11-13 | 2022-05-13 | 北京大学 | Multi-specific biological coupling connecting arm and synthetic method thereof |
CN114605367B (en) * | 2020-12-03 | 2023-06-27 | 中国人民解放军军事科学院军事医学研究院 | Coumarin-containing linker and antibody-conjugated drug containing the same |
CN112535678A (en) * | 2020-12-28 | 2021-03-23 | 烟台大学 | Trituzumab-linked maytansine nanoparticle composition |
CN112675313A (en) * | 2020-12-28 | 2021-04-20 | 烟台大学 | Trituzumab-trastuzumab-fragment-linked maytansine nanoparticle composition |
CN112675305B (en) * | 2021-01-22 | 2023-05-23 | 中国科学院深圳先进技术研究院 | Amphiphilic molecule self-assembled nano-drug for tumor treatment and preparation method and application thereof |
CA3213295A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
BR112023019420A2 (en) | 2021-03-23 | 2023-10-24 | Nuvation Bio Inc | ANTI-CANCER NUCLEAR HORMONE RECEPTOR TARGETING COMPOUNDS |
CN114106088A (en) * | 2021-04-28 | 2022-03-01 | 联宁(苏州)生物制药有限公司 | Bromomethylpyrazine-based drug conjugates and ADCs |
WO2022078524A2 (en) * | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
CN114533669B (en) * | 2022-01-18 | 2022-11-04 | 武汉大学 | Oral care composition and preparation method and application thereof |
WO2024073106A1 (en) * | 2022-09-29 | 2024-04-04 | Tract Pharmaceuticals, Inc. | Compounds and compositions useful as inhibitors of taps |
CN116754760B (en) * | 2023-06-14 | 2024-01-26 | 之江实验室 | Method for coupling 2, 4-Dinitrophenol (DNP) with controlled cleavage of antibody |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011038159A2 (en) * | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
WO2014080251A1 (en) * | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
WO2014197854A1 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
WO2015113476A1 (en) * | 2014-01-29 | 2015-08-06 | 上海恒瑞医药有限公司 | Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof |
WO2015151080A2 (en) * | 2015-07-04 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Specific conjugation of a cell-binding molecule |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL45594A (en) * | 1973-11-12 | 1977-12-30 | Stauffer Chemical Co | Bis-substituted succinamides and their use as herbicides |
AU2012348017A1 (en) * | 2011-12-05 | 2014-07-03 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
EP2822597A1 (en) * | 2012-03-09 | 2015-01-14 | UCL Business Plc. | Chemical modification of antibodies |
HUE048574T2 (en) * | 2012-07-12 | 2020-08-28 | Hangzhou Dac Biotech Co Ltd | Conjugates of cell binding molecules with cytotoxic agents |
-
2015
- 2015-08-10 WO PCT/IB2015/056083 patent/WO2015155753A2/en active Application Filing
- 2015-08-10 CA CA2991975A patent/CA2991975C/en active Active
- 2015-08-10 JP JP2018506984A patent/JP6817288B2/en active Active
- 2015-08-10 CN CN202210788010.0A patent/CN115300640A/en active Pending
- 2015-08-10 CN CN201580082582.5A patent/CN108289964B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011038159A2 (en) * | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
WO2014080251A1 (en) * | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
WO2014197854A1 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
WO2015113476A1 (en) * | 2014-01-29 | 2015-08-06 | 上海恒瑞医药有限公司 | Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof |
WO2015151080A2 (en) * | 2015-07-04 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Specific conjugation of a cell-binding molecule |
Also Published As
Publication number | Publication date |
---|---|
WO2015155753A2 (en) | 2015-10-15 |
CN108289964B (en) | 2022-08-12 |
CN115300640A (en) | 2022-11-08 |
CN108289964A (en) | 2018-07-17 |
CA2991975A1 (en) | 2015-10-15 |
CA2991975C (en) | 2021-04-06 |
JP2018532695A (en) | 2018-11-08 |
JP6817288B2 (en) | 2021-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015155753A3 (en) | Novel linkers and their uses in specific conjugation of drugs to biological molecule | |
PH12018501638A1 (en) | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | |
WO2015151081A3 (en) | Bridge linkers for conjugation of cell-binding molecules | |
AU2022228122B2 (en) | Interleukin-21 muteins and methods of treatment | |
EP3949969A3 (en) | Benzazepine compounds, conjugates, and uses thereof | |
PH12019502278A1 (en) | Conjugation of a cytotoxic drug with bis-linkage | |
PH12019501056A1 (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
ZA201903062B (en) | Amanitin antibody conjugates | |
WO2019010222A3 (en) | Polynucleotides encoding immunostimulatory fusion molecules and uses thereof | |
ZA201805336B (en) | Amanitin conjugates | |
PH12018501777A1 (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
WO2015151080A3 (en) | Specific conjugation of cell-binding molecules | |
PH12018500693A1 (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
WO2016147031A3 (en) | Novel hydrophilic linkers and ligand-drug conjugates thereof | |
WO2019136180A3 (en) | Heteroduplex nucleic acid molecules and uses thereof | |
WO2018098269A3 (en) | Peptide-containing linkers for antibody-drug conjugates | |
MY195368A (en) | A Conjugation Linker Containing 2,3-Diaminosuccinyl Group | |
PH12016501995A1 (en) | Tubulysin derivatives | |
MX2020009857A (en) | Il-2 conjugates. | |
JOP20190155A1 (en) | Antibody drug conjugates for ablating hematopoietic stem cells | |
MX2020012679A (en) | Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof. | |
ZA202001747B (en) | Psma-targeting amanitin conjugates | |
WO2017180789A3 (en) | Methods of treatment using chlorotoxin conjugates | |
MX2021007706A (en) | Conjugates of pattern recognition receptor agonists. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2991975 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018506984 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15776256 Country of ref document: EP Kind code of ref document: A2 |